Klastersky Jean, Paesmans Marianne, Georgala Aspasia, Muanza Frédérique, Plehiers Barbara, Dubreucq Laurent, Lalami Yassine, Aoun Michel, Barette Martine
Institut Jules Bordet, Bruxelles, Belgium.
J Clin Oncol. 2006 Sep 1;24(25):4129-34. doi: 10.1200/JCO.2005.03.9909.
Since febrile neutropenic patients were recognized to constitute a heterogeneous population, several models have been developed for predicting the risk of serious medical complications. The Multinational Association for Supportive Care in Cancer score and its derived clinical prediction rules have been validated, but thus far there were no data about its use for simplifying therapy in predicted low-risk patients.
In a single institution, we followed all episodes of febrile neutropenia between January 1999 and November 2003. Those patients predicted at low risk for complications, who were not receiving antibacterials at fever onset and were eligible for treatment with oral antibiotics, were treated with ciprofloxacin and amoxicillin-clavulanate and were discharged if they were clinically stable or improving after an initial observation period. The primary end point of the study was the rate of resolution of the febrile neutropenic episode without complications, among these early discharged patients.
Of 383 first febrile neutropenic episodes predicted at low risk of complication, 178 patients (33 men and 145 women, mainly with solid tumors) were treated orally; they constituted the basis of our analysis. Seventy-nine patients (44%) were discharged early (with a median time to discharge of 26 hours); no complications occurred among them but three patients had to be readmitted, resulting in a success rate of 96% (95% CI, 92% to 100%).
Our study shows that oral therapy followed by early discharge was feasible in a small but significant proportion of patients selected by a strategy combining predicted low risk and medical and nonmedical criteria.
由于发热性中性粒细胞减少症患者被认为是一个异质性群体,因此已开发出多种模型来预测严重医疗并发症的风险。癌症支持治疗多国协会评分及其衍生的临床预测规则已得到验证,但迄今为止,尚无关于其用于简化预测低风险患者治疗的数据。
在一家单一机构中,我们追踪了1999年1月至2003年11月期间所有发热性中性粒细胞减少症发作情况。那些被预测为并发症低风险、发热开始时未接受抗菌药物治疗且有资格接受口服抗生素治疗的患者,接受环丙沙星和阿莫西林-克拉维酸治疗,若在初始观察期后临床稳定或病情改善则出院。该研究的主要终点是这些早期出院患者中无并发症的发热性中性粒细胞减少症发作的缓解率。
在383例首次发热性中性粒细胞减少症发作中,预测并发症风险低的患者有178例(33例男性和145例女性,主要为实体瘤患者)接受了口服治疗;他们构成了我们分析的基础。79例患者(44%)早期出院(出院中位时间为26小时);他们中无并发症发生,但有3例患者不得不再次入院,成功率为96%(95%CI,92%至100%)。
我们的研究表明,对于通过结合预测低风险以及医学和非医学标准策略选择出的一小部分但相当比例的患者,口服治疗后早期出院是可行的。